ACC 22: Results from the TRANSLATE-TIMI 70 Trial | Dr Brian Bergmark

Подробнее о видео

Watch on Radcliffe Cardiology:

In this short interview from our coverage of the ACC 22 late-breaking trials, Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US) discusses the data from the TRANSLATE-TIMI 70 study; a phase 2b, randomised trial of Vupanorsen (an antisense oligonucleotide).
The primary objective was to evaluate the effect of Vupanorsen on non-high-density lipoprotein (non-HDL-C) levels in statin-treated patients with elevated cholesterol (NCT04516291).

Discussion Points:
-Importance of this Trial
-Study Design and Patient Cohort
-Outcomes of this Study
-Take-home Messages for Clinicians
-Next Steps

Recorded remotely from ACC, Washington DC, 2022.
Interviewer: Mirjam Boros

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.